43 domestically developed innovative drugs and 66 innovative medical devices were approved for market—setting a new record. Licensing deals for Chinese innovative drugs also hit new highs. Industry collaboration intensified, cross-disciplinary technology integration accelerated, and the innovation ecosystem thrived.

On May 9–10, 2025, in Suzhou, Jiangsu Province, the professional healthcare service organization Artery Network, together with VB100 and the Eggshell Research Institute, officially released the “2025 Future Healthcare 100” list. The list reflects key breakthroughs in medical and healthcare innovation over the past year and aims to reveal industry development trends.

The “Future Healthcare 100” is one of the most authoritative rankings in China’s healthcare sector. Using a professional evaluation model across multiple dimensions—including company valuation, resource capacity, market performance, innovation capability, commercial value, and future prospects—it evaluates companies in fields such as innovative pharmaceuticals and medical devices. Enterprises selected are recognized as leaders at the cutting edge of industry innovation, with widely acknowledged R&D and business models.

Wuhan Hzymes Biotechnology Co., Ltd. earned a spot in the top 100 in “Medical Industry Chain Services Companies” for its breakthroughs and achievements in core raw materials for biopharmaceuticals.

Since its founding in 2015, Hzymes has focused on the independent development and production of core enzyme raw materials for biopharmaceuticals, breaking the technical monopoly held by global giants in the field of specialty enzymes. Based on five core technology platforms—enzyme gene mining, molecular design, high-throughput screening, scalable production, and application development—the company has developed over 400 types of enzymes for in vitro diagnostics and biopharmaceutical use, and has filed over 200 patent applications.

During the COVID-19 pandemic, the company rapidly achieved large-scale production of critical enzyme Proteinase K, reaching an annual capacity of 1,500 kg. The product cost was reduced by 50% compared to imported versions and was exported to over 30 countries, contributing significantly to global pandemic response and laying the foundation for global market entry.

As one of the few Chinese suppliers covering the full spectrum of in vitro diagnostics, biopharma, life sciences, and international expansion, Hzymes has built large R&D and production bases and marketing centers in Wuhan, Shanghai, and Yichang. The company has created a comprehensive industry chain from R&D and manufacturing to technical services and sales. Its team continues to grow, with nearly 50% of employees engaged in R&D, and has completed a Series C financing round of nearly 800 million RMB, further enhancing its innovation momentum.

Innovation-Driven: Winning by Stability, Succeeding with Long-Term Vision

“Technological breakthroughs are the key to breaking monopolies. Don’t idolize foreign companies—performance speaks louder than reputation.”

Today, many of Hzymes’ core product indicators surpass imported alternatives. The company’s AI-based enzyme molecular design platform and ultra-high-throughput screening system (boosting efficiency by 1,000x) have reduced R&D timelines from 3 years to just 6 months. Several enzyme products now fully substitute for imports, supporting domestic self-reliance and securing the biopharma supply chain.

“The future of the industry won’t follow just one model—but tech-driven innovation will always be our strongest moat.”

These dual accolades showcase Hzymes’ growing technological strength and industry influence. The company will continue to uphold its core values—Customer First, Innovation, Excellence, Responsibility, and Win-Win—while investing in synthetic biology, AI-assisted enzyme design, and breakthroughs in diagnostics. By working with upstream and downstream partners, it aims to help define a “China Standard” for biopharmaceutical raw materials.